Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
August 14, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
August 07, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Presented Preliminary Clinical Data on RX-3117 in Bladder Cancer at the American Society of Clinical Oncologists (ASCO) Annual Meeting Strengthened Financial Position with a $10 million Registered...
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
July 10, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., July 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Announces $10 Million Registered Direct Offering
June 07, 2017 08:50 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into definitive agreements with institutional investors to purchase...
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
June 04, 2017 09:00 ET
|
Rexahn Pharmaceuticals
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Metastatic Bladder Cancer Resistant to Gemcitabine who had Failed on Multiple Prior...
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
May 08, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Effects 1-for-10 Reverse Stock Split
May 05, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” or the “Company”), a clinical stage biopharmaceutical company developing innovative, targeted...
Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 04, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Completed Phase I dose-escalation study with Supinoxin™ in solid tumors Initiated Phase IIa clinical trial of Supinoxin in Metastatic Triple Negative Breast Cancer ROCKVILLE, Md., May 04, 2017 ...
Rexahn Announces 1-for-10 Reverse Stock Split
April 13, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update
February 27, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Progressed Three Novel Targeted Anti-Cancer Therapies in Clinical Development Completed stage 1 and initiated stage 2 of Phase IIa clinical trial of RX-3117 in Relapsed and Refractory Metastatic...